The endocannabinoid network is a complicated physiologic system that affects metabolic pathways in the body. Cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor found in brain and peripheral tissues. Selective antagonism at this receptor could target multiple tissues involved in metabolic homeostasis. In clinical trials with obese patients, treatment with this receptor was associated with meaningful weight loss, improved serum lipids and glycemic control.
Description
Cannabinoid receptor type 1 (CB1) is a G protein-coupled cannabinoid receptor encoded by the CNR1 gene. Through a detailed process involving the synthetization and testing of hundreds of antagonists, University of Pittsburgh researchers have now completed testing of over 300 novel CB1 antagonists that are structurally distinct from all prior classes, which indicates this discovery holds vast potential for additional treatments and uses within the complex physiologic system.
Applications
· For use in complicated physiologic systems that affect metabolic pathways
Advantages
· Structurally distinct from all prior classes
· Holds potential for new treatments and uses
Invention Readiness
In vitro
IP Status
https://patents.google.com/patent/US20240000806A1
